Genetic Evidence Suggests GLP-1 Drugs May Help with Obstructive Sleep Apnea | Research

The takeaway

Mendelian randomization using GLP-1R gene variants as proxies found a genetic association between GLP-1 receptor activation and reduced obstructive sleep apnea risk.

50,200 OSA cases
FinnGen data used in Mendelian randomization showing GLP-1 receptor activation linked to reduced OSA

What the researchers found

Mendelian randomization found a genetic association between GLP-1 receptor activation and reduced obstructive sleep apnea risk.

Why it matters

If GLP-1 drugs reduce OSA risk beyond just weight loss, they could address a condition affecting hundreds of millions worldwide.

The numbers in context

FinnGen R11: 50,200 OSA cases, 401,484 controls; cis-eQTLs for GLP1R gene used as genetic proxies; IVW method primary analysis.

How the study worked

Two-sample Mendelian randomization using GLP1R cis-eQTLs as genetic instruments, validated against T2DM and BMI, with FinnGen OSA data.

Who was studied

European ancestry adults from FinnGen (50,200 OSA cases)

What this study cannot tell us

Mendelian randomization assumes genetic instruments are valid proxies for drug effects. Cannot determine the mechanism (weight loss vs direct effect).

How to read the evidence

Mendelian randomization — stronger than observational studies for causal inference but cannot replace clinical trials.

When this study was published

Published in 2025, providing genetic support for GLP-1 drugs in sleep apnea.

The bigger picture

This genetic evidence supports clinical trials testing GLP-1 drugs specifically for OSA, potentially beyond their weight loss effects.

Questions still open

Is the OSA benefit mediated entirely through weight loss or is there a direct GLP-1 receptor effect?
Which GLP-1 drug would be most effective for OSA?

Common questions

Could GLP-1 drugs help with sleep apnea?

Genetic evidence suggests yes — people with gene variants that mimic GLP-1 drug effects appear to have lower sleep apnea risk.

What is Mendelian randomization?

A genetic method that uses inherited gene variants as natural experiments to test whether a drug target causes a disease outcome — similar to a genetic clinical trial.

Read the original research

Effect of Glucagon-Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea.

Obesity science & practice, 11(4), e70090

View on PubMed ↗Publisher’s paper ↗

Citation

Qian, Bei-Bei; Huang, Yu-Jie; Yan, Cai-Feng; Feng, Shang-Yong; She, Dun-Min. (2025). Effect of Glucagon-Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea.. Obesity science & practice, 11(4), e70090. https://doi.org/10.1002/osp4.70090